Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-934-1 | CAS number: 129-17-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Fluctuation test was performed for the test chemical Patent blue V used at a concentration of 500 mg/kg in liquid medium for72-96 hrs. The tester strains used were Salmonella typhimurium TA 1538 and Escherichia coli WP2uvrA. The assay was performed for each bacterium in three separate experiments.
The given test material failed to inducegenotoxicity in the bacteriaSalmonella typhimuriumTA 1538 andEscherichia coliWP2uvrA.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Data is from peer reviewed journal
- Qualifier:
- according to guideline
- Guideline:
- other: Data is from Journal with permission
- Principles of method if other than guideline:
- The induction of mutations was studied in modified liquid fluctuation tests using a tryptophan-requiring E. coli strain (sensitive tobase substitutions) and a histidine auxotroph of Salmonella typhimurium (specific for frameshifts)for the test compound Patent Blue V.
- GLP compliance:
- not specified
- Type of assay:
- bacterial gene mutation assay
- Target gene:
- Modified Liquid Fluctuation test:Salmonella typhimurium TA 1538 and Escherichia coli WP2 uvrA
- Species / strain / cell type:
- E. coli WP2 uvr A
- Details on mammalian cell type (if applicable):
- Not applicable
- Additional strain / cell type characteristics:
- not specified
- Species / strain / cell type:
- S. typhimurium TA 1538
- Details on mammalian cell type (if applicable):
- Not applicable
- Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Test concentrations with justification for top dose:
- 500 mg/L
- Vehicle / solvent:
- Deionised water
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- not specified
- Positive control substance:
- not specified
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in mediumDURATION- Preincubation period: No data available - Exposure duration: 72-96 hrs- Expression time (cells in growth medium): 72-96 hrs- Selection time (if incubation with a selection agent): No data available- Fixation time (start of exposure up to fixation or harvest of cells): No data availableSELECTION AGENT (mutation assays): No data availableSPINDLE INHIBITOR (cytogenetic assays): No data availableSTAIN (for cytogenetic assays): No data availableNUMBER OF REPLICATIONS: TriplicateNUMBER OF CELLS EVALUATED: No data availableDETERMINATION OF CYTOTOXICITY- Method: mitotic index; cloning efficiency; relative total growth; other: No data availableOTHER EXAMINATIONS:- Determination of polyploidy: No data available- Determination of endoreplication: No data available- Other: No data available OTHER: The food colour was made up in deionized water and membrane-sterilized prior to use. The test material was tested at its maximum sublethal concentration.
- Evaluation criteria:
- The test material was considered positive only if it resulted in significant more turbid tubes in a treated series when compared with an untreated set of tubes
- Statistics:
- Chi square test
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- not specified
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not specified
- Positive controls validity:
- not specified
- Species / strain:
- S. typhimurium TA 1538
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- not specified
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not specified
- Positive controls validity:
- not specified
- Additional information on results:
- No data
- Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):negative with and withoutPatent blue V failed to induce gene mutation in the bacterial tester strains Salmonella typhimurium TA 1538 and Escherichia coli WP2 uvrA
- Executive summary:
- Fluctuation test was performed for the test chemical Patent blue V used at a concentration of 500 mg/kg in liquid medium for 72-96 hrs. The tester strains used were Salmonella typhimurium TA 1538 and Escherichia coli WP2 uvrA. The assay was performed for each bacterium in three separate experiments.
The given test material failed to induce genotoxicity in the bacteria Salmonella typhimurium TA 1538 and Escherichia coli WP2 uvrA and hence does not classify for gene mutation in vitro.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
Additional information from genetic toxicity in vitro:
Gene mutation in vitro:
Various peer reviewed publications were reviewed to determine the mutagenic nature of the test compound Patent blue V in vitro. The study is as summarized below:
Salmonella/ mammalian microsome mutagenicity assay was performed by Bonin et al (1981) to study the mutagenic potential of Patent Blue V (CAS no 129-17-9) both in the presence and absence of metabolic activator S9 mix. To each 2 ml of top agar at 42°C was added 100 µL bacterial broth culture, 100 µL test compound dissolved in DMSO various concentrations, and 500 µL S9 mix as required. Plates were incubated at 37°C for 72 hrs before counting his+revertant colonies and each dose point was determined from at least two plates, unless indicated otherwise. Criteria for mutagenicity were (a) a dose-response and, (b) reproducibility of the result. Dose-responses were not always evident at concentratrations selected for initial testing. Since no mutagenicity was detected, Patent Blue V is negative for the induction of gene toxicity in vitro. Hence the test chemical is not likely to classify for gene mutation in vitro.
Fluctuation test was performed (Haveland- Smith, 1979) for the test chemical Patent blue V (CAS no 129-17-9) used at a concentration of 500 mg/L in liquid medium for 72-96 hrs. The tester strains used wereSalmonella typhimuriumTA 1538 andEscherichia coliWP2uvrA. The assay was performed for each bacterium in three separate experiments. The given test material failed to induce genotoxicity in the bacteriaSalmonella typhimuriumTA 1538 andEscherichia coliWP2uvrA and hence does not classify for gene mutation in vitro.
Patent Blue V (CAS no 129-17-9) was used at a concentration of 5000 mg/L and its genotoxic effect was studied (Haveland- Smith, 1979) in the bacteriaE. coli strains WP2 trp uvrA and WP100 trp uvrA recAbyrecplate assay in the agar medium. The given test material is negative for genotoxicity in the bacteriaE. coli strains WP2 trp uvrA and WP100 trp uvrA recAand hence is not likely ti classify for gene mutation in vitro.
An Ames test with Patent Blue V (CAS no 129-17-9) was performed (EFSA Journal, 2013) according to the OECD guideline No. 471. Five histidine-dependent strains of S. typhimurium (TA98, TA100, TA1535, TA1537 and TA102) were used to evaluate the mutagenic potential of Patent Blue V, both in the absence and presence of rat liver S9 metabolism. The study was carried out using both the plate incorporation and the pre-incubation methods. Patent Blue V was tested as a dark blue solution in water for injection. The experiment performed using the plate incorporation method was carried out using the dose range of 52-5000 µg/plate, both in the absence and presence of rat S9 metabolism. Following treatment, no precipitation and cytotoxicity were noted in the absence or in the presence of metabolic activation. Statistically and biologically significant increases in the number of revertants were observed only with the TA98 tester strain in the presence of metabolic activation. Patent Blue V is positive to induce mutation only in theSalmonella typhimuriumTA98 strain in the presence of S9 metabolic activation system. The positive outcome obtained in the presence of metabolic activation and at higher dose levels only, strongly indicates that mutagenicity could have been caused by the presence of impurities given the low purity of the test item (86 %). It does not induce mutation in the strainsTA100, TA1535, TA1537 and TA102 in the presence or absence of S9 metabolic activation system. Hence the test chemical is not likely to classify as a gene mutant in vitro.
An Ames test with Patent Blue V (CAS no 129-17-9) was performed (EFSA Journal, 2013) according to the OECD guideline No. 471. Five histidine-dependent strains of S. typhimurium (TA98, TA100, TA1535, TA1537 and TA102) were used to evaluate the mutagenic potential of Patent Blue V, both in the absence and presence of rat liver S9 metabolism. The study was carried out using both the plate incorporation and the pre-incubation methods. Patent Blue V was tested as a dark blue solution in water for injection. The pre-incubation method was carried out in the dose range of 492-5000 µg/plate, both in the absence and presence of rat liver S9 metabolism. Following treatment, no precipitation or cytotoxicity were noted in the absence or in the presence of metabolic activation. Statistically and biologically significant increases in the number of revertants were confirmed with the TA98 tester strain in the presence of metabolic activation. The positive outcome obtained in the presence of metabolic activation and at higher dose levels only, strongly indicates that mutagenicity could have been caused by the presence of impurities given the low purity of the test item (86 %). Patent Blue V is positive to induce mutation only in the Salmonella typhimurium TA98 strain in the presence of S9 metabolic activation system. It does not induce mutation in the strains TA100, TA1535, TA1537 and TA102 in the presence or absence of S9 metabolic activation system. Hence, the test material is not likely to classify a gene mutant in vitro.
The mutagenic potential of Patent Blue V (CAS no 129-17-9) was assessed (EFSA Journal, 2013) in the in vitro mammalian cell gene mutation assay using L5178Y (Tk+/-) mouse lymphoma cells. The study was conducted in compliance with the OECD guideline No. 476 and the ICH guidelines S2A and S2B. Long treatment (approximately 24 hours) without metabolic activation was performed. Replicate cultures were set up at each experimental point. No statistically or biologically significant increases in the mutant frequency were noted up to the maximum tested dose level of 2500 μg/ml at any treatment time in the absence of metabolic activation. Patent Blue V does not induce mutation in the L5178Y (Tk+/-) mouse lymphoma cells in the absence of S9 metabolic activation system. Hence the test material is not likely to classify as a gene mutant in vitro.
The mutagenic potential of Patent Blue V (CAS no 129-17-9) was assessed (EFSA Journal, 2013) in the in vitro mammalian cell gene mutation assay using L5178Y (Tk+/-) mouse lymphoma cells. The study was conducted in compliance with the OECD guideline No. 476 and the ICH guidelines S2A and S2B. Short treatment (approximately 4 hours) with and without metabolic activation was performed. Replicate cultures were set up at each experimental point. No statistically or biologically significant increases in the mutant frequency were noted up to the maximum tested dose level of 2500 μg/ml at any treatment time in the presence or absence of metabolic activation. Patent Blue V does not induce mutation in the L5178Y (Tk+/-) mouse lymphoma cells in the presence or absence of S9 metabolic activation system. Hence the test compound is not likely to classify as a gene mutant in vitro
Gene mutation in vivo:
Various references for the test compound and the prediction data are used to summarize the mutageinc nature of the test compound in vivo:
The DNA damaging capabilities of Patent Blue V (E 131) (CAS no 129-17-9)were assessed (EFSA Journal, 2013) in the in vivo single cell gel/Comet assay in rats. Patent Blue V (E 131) was examined for genotoxic properties by evaluating the induction of DNA damage in cell suspensions isolated from liver, jejunum/ileum and peripheral blood of rats after in vivo treatment using the alkaline (pH>13) version of the Comet Assay. In the main experiment, only male animals were treated since no substantial inter-sex differences in toxicity were observed. Groups of 5 Sprague-Dawley male rats were treated twice at 24 hour intervals with the vehicle only (sterile distilled water of injectable grade), or Patent Blue V (E 131) at the dose levels of 500, 1000 and 2000 mg/kg/day. Ethyl methanesulphonate (EMS), at 200 mg/kg/day served as positive control. Animals were sacrificed approximately 3-4 hours after the second dosing. Peripheral blood and cell suspensions isolated from liver and jejunum/ileum were embedded in agarose gel on microscope slides. No statistically significant increases in tail moment and tail intensity values compared with the vehicle control values were observed at any dose-level in the treated groups. Patent Blue V (E 131) does not induce any effect on DNA migration in rat liver, jejunum/ileum and peripheral blood. The given test material gives negative gene toxicity in vivo response on the Sprague Dawley male rats and hence is not likely to classify for gene mutation in vivo.
The mutagenic potential of Patent Blue V (CAS no 129-17-9)was assessed (EFSA Journal, 2013) in the in vivo bone marrow micronucleus assay in Sprague-Dawley rats. On the basis of a preliminary experiment in which mortality was observed at 600 mg/kg bw, the study was carried out using groups of 5 male and 5 female rats administered dose levels of 75, 150 and 300 mg/kg, by a single intravenous injection. Saline (0.9 % NaCl) was used as vehicle. Animals were sacrificed 24 and 48 hours after administration. Clinical signs were noted only at the highest dose level of 300 mg/kg bw and consisted of irregular breathing and/or lowered activity in some animals. When compared to the negative control group (0.9 % NaCl), no biologically significant decreases in the polychromatic/normochromatic erythrocytes ratio (PCEs/NCEs) were noted in any animal treatment groups. For either sex or both sexes combined, when compared to the negative control group (0.9 % NaCl), no biologically significant increase in the mean frequencies of micronucleated polychromatic erythrocytes (MNPCEs) was noted in the animal groups treated with Patent Blue V up to the highest dose level of 300 mg/kg. Patent Blue V does not prove to induce micronuclei in rat bone marrow erythrocytes and hence is negative for inducing mutation in vivo.
In vivo bone marrow chromosome aberration assay was performed (CAS no 129-17-9) in C57Bl6 mice to assess for the potential clastogenicity activity of Patent Blue V (EFSA Journal, 2013). The test item was administered by oral gavage at daily dose levels of 0.08 and 0.8 mg/kg bw for 5 days. Animals were sacrificed 6 hours after the administration of the last dose level. Mice also received colchicines in the last 2 hours at 2.5 mg/kg bw to accumulate cells in metaphases. A minimum number of 100 well spread metaphases were scored for each animal in the control and treated groups. Results obtained indicated that Patent Blue V did not induce statistically significant increases of chromosomal aberrations in the mouse bone marrow cells erythrocytes. The given test material gives negative gene toxicity in vivo response in mice and hence is not likely toclassify for gene mutation in vivo.
Based on the available data summarized, the test chemical patent Blue V is not likely to classify as a gene mutant in vitro and in vivo. Though some mutagenic activity is reported for the test chemical in the data summarized for in vitro toxicity but it has been strongly indicated that mutagenicity could have been caused by the presence of impurities given the low purity of the test item. Thus the test chemical is likely to be not classififed for gene mutation.
Justification for selection of genetic toxicity endpoint
Data from K2 publication
Justification for classification or non-classification
Based on the available data summarized, the test chemical patent Blue V is not likely to classify as a gene mutant in vitro and in vivo.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.